Sign in →

Test Code NCYB Recessive Congenital Methemoglobinemia, CYB5 and CYB5 Reductase Genetic Analysis, Next-Generation Sequencing, Varies


Ordering Guidance


This test should be performed after more common causes of methemoglobinemia have been eliminated. To assess for more common causes of methemoglobinemia, order MEV1 / Methemoglobinemia Evaluation, Blood.

 

Testing for the CYB5A and CYB5R3 genes as part of a customized panel is available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

 

Multiple gene panels are available. For more information see NHEP and Subpanel Comparison Gene List.

 

Targeted testing for familial variants (also called site-specific or known variants testing) is available for the CYB5A and CYB5R3 genes. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.



Additional Testing Requirements


This test is best interpreted in the context of protein functional findings by enzymatic assay and complete blood cell count analysis. This complete interpretation can be provided by also ordering the MEV1 / Methemoglobinemia Evaluation, Blood. Fill out the information sheet and indicate that a next-generation sequencing test was also ordered. Providing complete blood cell count data and clinical notes will also allow more precise interpretation of results.



Shipping Instructions


Specimen preferred to arrive within 96 hours of collection.



Necessary Information


1. Metabolic Hematology Next-Generation Sequencing (NGS) Patient Information is required. Testing may proceed without the patient information; however, the information aids in providing a more thorough interpretation. Ordering providers are strongly encouraged to fill out the form and send with the specimen.

2. If form not provided, include the following information with the test request: clinical diagnosis, pertinent clinical history (ie, complete blood cell count results and relevant clinical notes), and differentials based on clinical presentation and/or laboratory findings.



Specimen Required


Specimen Type: Whole blood

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Container/Tube:

Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated


Forms

1. Metabolic Hematology Next-Generation Sequencing (NGS) Patient Information (T816) is required.

2. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available.

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing (Spanish) (T826)

3. If not ordering electronically, complete, print, and send a Benign Hematology Test Request (T755) with the specimen.

Secondary ID

618977

Useful For

Providing a genetic evaluation for patients with a personal or family history suggestive of recessive congenital methemoglobinemia

 

Genotype confirmation of borderline cytochrome b5 reductase (methemoglobin reductase: METR) enzyme activity levels

 

Identifying variants within the CYB5 and CYB5 reductase genes (CYB5A, CYB5R3) allowing for further genetic counseling

Genetics Test Information

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in the CYB5A and CYB5R3 genes associated with autosomal recessive congenital methemoglobinemia. See Method Description for additional details.

 

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, recurrence risk assessment, familial screening, and genetic counseling for congenital methemoglobinemia.

Testing Algorithm

Genetic testing for congenital methemoglobinemia is indicated if:

-There is cyanosis in the setting of clinically stable patient ("more blue than sick")

-Methemoglobin reductase (cytochrome b5 reductase) activity is decreased

-Hemoglobin electrophoresis, particularly high-performance liquid chromatography testing, is negative

Method Name

Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing.

Reporting Name

CYB5 and CYB5 Reductase, NGS

Specimen Type

Varies

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Clinical Information

Methemoglobin forms when the hemoglobin (Hb) molecule contains iron in the ferric (Fe3[+]) form, which cannot carry oxygen. Methemoglobin is converted back to the functional ferrous state (Fe2[+]) by the enzyme cytochrome b5 reductase (methemoglobin reductase). Methemoglobinemia can be hereditary or acquired and is present when methemoglobin levels exceed the normal range. Acquired methemoglobinemia results after toxic exposure to nitrates and nitrites/nitrates (fertilizer, nitric oxide), topical anesthetics ("caines"), dapsone, naphthalene (moth balls/toilet deodorant cakes), and industrial use of aromatic compounds (aniline dyes).

 

Congenital methemoglobinemias are rare and are characterized by lifelong cyanosis. They are due either to an intrinsic structural disorders of hemoglobin, called M-Hbs (autosomal dominant inheritance)(1,2); or a deficiency of cytochrome b5 reductase (methemoglobin reductase) in erythrocytes (autosomal recessive inheritance). The hemoglobin genes, HBA1/HBA2 and HBB, are not assessed in this assay.

 

Recessive congenital methemoglobinemia results from genetic variants in either CYB5R3 or CYB5A and is described as type I, type II, or methemoglobinemia and ambiguous genitalia (previously type IV).(1-4) Methemoglobinemia type I results from alterations to CYB5R3 with clinical impact exclusive to the red blood cells (erythrocytes) and typically presents as asymptomatic, well tolerated cyanosis. Methemoglobinemia type II also results from alterations to CYB5R3; however, it is due to alterations that lower activity or expression of the enzyme in all tissues. Methemoglobin type II is a more severe condition associated with cyanosis, neurological impairment, and altered lipid metabolism. Methemoglobinemia and ambiguous genitalia (previously type IV) is a very rare autosomal recessive condition caused by deleterious alterations of the CYB5A gene that produce an isolated 17,20-lyase deficiency. In addition to mild to severe methemoglobinemia, individuals with this condition have been reported to have male under-masculinization/ambiguous genitalia and absent/disturbed pubertal development.

Reference Values

An interpretive report will be provided.

Interpretation

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(5) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Day(s) Performed

Varies

Report Available

28 to 42 days

Specimen Retention Time

Whole blood: 2 weeks (if available); Extracted DNA: 3 months

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81479

LOINC Code Information

Test ID Test Order Name Order LOINC Value
NCYB CYB5 and CYB5 Reductase, NGS 103737-3

 

Result ID Test Result Name Result LOINC Value
618978 Test Description 62364-5
618979 Specimen 31208-2
618980 Source 31208-2
618981 Result Summary 50397-9
618982 Result 82939-0
618983 Interpretation 59465-5
618984 Additional Results 82939-0
618985 Resources 99622-3
618986 Additional Information 48767-8
618987 Method 85069-3
618988 Genes Analyzed 82939-0
618989 Disclaimer 62364-5
618990 Released By 18771-6